Cargando…

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner

The DNA-alkylating cytotoxic agent cyclophosphamide (CTX) is commonly used in the clinic to treat hematological malignancies like lymphomas and leukemias as well as solid tumors, but shows dose-dependent potentially life-threatening toxicities and can induce secondary malignancies. Thus, the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexandrova, Evguenia M, Xu, Sulan, Moll, Ute M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386516/ https://www.ncbi.nlm.nih.gov/pubmed/28300840 http://dx.doi.org/10.1038/cddis.2017.108

Ejemplares similares

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Mutant p53 – Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival
por: Alexandrova, Evguenia M., et al.
Publicado: (2015)

Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins
por: Tutuska, Karis, et al.
Publicado: (2020)

Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment
por: Alexandrova, EM, et al.
Publicado: (2015)

Smad4 and p53 synergize in suppressing autochthonous intestinal cancer
por: Park, Jun Won, et al.
Publicado: (2022)

Ganetespib: research and clinical development
por: Jhaveri, Komal, et al.
Publicado: (2015)

Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib
por: Kallu, Jyothi, et al.
Publicado: (2019)

Ganetespib radiosensitization for liver cancer therapy
por: Chettiar, Sivarajan T., et al.
Publicado: (2016)

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
por: Schulz-Heddergott, Ramona, et al.
Publicado: (2018)

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus
por: Liu, Yuan, et al.
Publicado: (2015)

Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models
por: Álvarez-León, Winniberg, et al.
Publicado: (2021)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
por: Wu, Xinqi, et al.
Publicado: (2013)

Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner
por: Yang, Fan, et al.
Publicado: (2021)

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner
por: Li, Ying, et al.
Publicado: (2022)

Rotenone aggravates PD-like pathology in A53T mutant human α-synuclein transgenic mice in an age-dependent manner
por: Chen, An-Di, et al.
Publicado: (2022)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
por: Landmann, H, et al.
Publicado: (2014)

Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner
por: Wang, Ren, et al.
Publicado: (2016)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53
por: Yan, H, et al.
Publicado: (2015)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
por: Liu, H, et al.
Publicado: (2015)

A Phase I Study of Ganetespib and Ziv‐Aflibercept in Patients with Advanced Carcinomas and Sarcomas
por: Meehan, Robert, et al.
Publicado: (2018)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

HSP90 Inhibitor Ganetespib (STA-9090) Inhibits Tumor Growth in c-Myc-Dependent Esophageal Squamous Cell Carcinoma
por: Guan, Liuliu, et al.
Publicado: (2020)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

SBDS(R126T) rescues survival of sbds(−/−) zebrafish in a dose-dependent manner independently of Tp53
por: Oyarbide, Usua, et al.
Publicado: (2023)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments
por: Scutigliani, Enzo M., et al.
Publicado: (2022)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

p53 further extends its reach
por: Zirngibl, Katharina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5tksnh8pq47egkmcubdkfblp32